CD4+ T cells in cancer
Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Normal cells explore multiple states to survive stresses encountered during development
and self-renewal as well as environmental stresses such as starvation, DNA damage, toxins …
and self-renewal as well as environmental stresses such as starvation, DNA damage, toxins …
Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer
KM Boehm, EA Aherne, L Ellenson, I Nikolovski… - Nature cancer, 2022 - nature.com
Patients with high-grade serous ovarian cancer suffer poor prognosis and variable response
to treatment. Known prognostic factors for this disease include homologous recombination …
to treatment. Known prognostic factors for this disease include homologous recombination …
Intratumoral heterogeneity in cancer progression and response to immunotherapy
Most (if not all) tumors emerge and progress under a strong evolutionary pressure imposed
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these …
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these …
Glioma progression is shaped by genetic evolution and microenvironment interactions
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify
treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA …
treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA …
[HTML][HTML] Ovarian cancer mutational processes drive site-specific immune evasion
High-grade serous ovarian cancer (HGSOC) is an archetypal cancer of genomic instability,,–
patterned by distinct mutational processes,, tumour heterogeneity,–and intraperitoneal …
patterned by distinct mutational processes,, tumour heterogeneity,–and intraperitoneal …
Neoantigen quality predicts immunoediting in survivors of pancreatic cancer
Cancer immunoediting is a hallmark of cancer that predicts that lymphocytes kill more
immunogenic cancer cells to cause less immunogenic clones to dominate a population …
immunogenic cancer cells to cause less immunogenic clones to dominate a population …
Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response
T Fu, LJ Dai, SY Wu, Y Xiao, D Ma, YZ Jiang… - Journal of hematology & …, 2021 - Springer
Tumors are not only aggregates of malignant cells but also well-organized complex
ecosystems. The immunological components within tumors, termed the tumor immune …
ecosystems. The immunological components within tumors, termed the tumor immune …
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200) …
E Pujade-Lauraine, K Fujiwara, JA Ledermann… - The Lancet …, 2021 - thelancet.com
Background Most patients with ovarian cancer will relapse after receiving frontline platinum-
based chemotherapy and eventually develop platinum-resistant or platinum-refractory …
based chemotherapy and eventually develop platinum-resistant or platinum-refractory …
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy
C Krishna, RG DiNatale, F Kuo, RM Srivastava… - Cancer cell, 2021 - cell.com
Clear cell renal cell carcinomas (ccRCCs) are highly immune infiltrated, but the effect of
immune heterogeneity on clinical outcome in ccRCC has not been fully characterized. Here …
immune heterogeneity on clinical outcome in ccRCC has not been fully characterized. Here …